CONTEXT AND OBJECTIVE: Strategies to augment pulsatile GH may be beneficial in patients with excess visceral adiposity, in whom GH secretion is reduced. The objective of this study was to determine the effects of a novel GHRH (GHRH(1-44)) analog, tesamorelin, on endogenous GH pulsatility and insulin sensitivity in healthy men. DESIGN, PARTICIPANTS, AND INTERVENTION: Thirteen males (mean age 45 ± 3 yr and body mass index 27.3 ± 1.2 kg/m(2)) receivedtesamorelin 2 mg sc once daily for 2 wk, with assessment made at baseline, after 2 wk of treatment, and after 2 wk of withdrawal. OUTCOME MEASURES: The primary end point was change in mean overnight GH as determined by overnight frequent sampling. Secondary end points included insulin-stimulated glucose uptake as measured by euglycemic hyperinsulinemic clamp; IGF-I; and GH secretion parameters, including pulse area, pulse frequency, and basal secretion. RESULTS:Tesamorelin treatment increased mean overnight GH (change +0.5 ± 0.1 μg/liter, P = 0.004), average log(10) GH peak area (change +0.4 ± 0.1 log(10) μg/liter, P = 0.001), and basal GH secretion (change +0.008 ± 0.003 μg/liter · min, P = 0.008). IGF-I increased by 181 ± 22 μg/liter (P < 0.0001). Neither fasting glucose (P = 0.93) nor insulin-stimulated glucose uptake (P = 0.61) was significantly affected by tesamorelin. CONCLUSIONS: Once-daily short-term treatment with a GHRH(1-44) analog, tesamorelin, augments basal and pulsatile GH secretion. Moreover, although tesamorelin significantly increases IGF-I, peripheral insulin-stimulated glucose uptake appears to be preserved.
RCT Entities:
CONTEXT AND OBJECTIVE: Strategies to augment pulsatile GH may be beneficial in patients with excess visceral adiposity, in whom GH secretion is reduced. The objective of this study was to determine the effects of a novel GHRH (GHRH(1-44)) analog, tesamorelin, on endogenous GH pulsatility and insulin sensitivity in healthy men. DESIGN, PARTICIPANTS, AND INTERVENTION: Thirteen males (mean age 45 ± 3 yr and body mass index 27.3 ± 1.2 kg/m(2)) received tesamorelin 2 mg sc once daily for 2 wk, with assessment made at baseline, after 2 wk of treatment, and after 2 wk of withdrawal. OUTCOME MEASURES: The primary end point was change in mean overnight GH as determined by overnight frequent sampling. Secondary end points included insulin-stimulated glucose uptake as measured by euglycemic hyperinsulinemic clamp; IGF-I; and GH secretion parameters, including pulse area, pulse frequency, and basal secretion. RESULTS: Tesamorelin treatment increased mean overnight GH (change +0.5 ± 0.1 μg/liter, P = 0.004), average log(10) GH peak area (change +0.4 ± 0.1 log(10) μg/liter, P = 0.001), and basal GH secretion (change +0.008 ± 0.003 μg/liter · min, P = 0.008). IGF-I increased by 181 ± 22 μg/liter (P < 0.0001). Neither fasting glucose (P = 0.93) nor insulin-stimulated glucose uptake (P = 0.61) was significantly affected by tesamorelin. CONCLUSIONS: Once-daily short-term treatment with a GHRH(1-44) analog, tesamorelin, augments basal and pulsatile GH secretion. Moreover, although tesamorelin significantly increases IGF-I, peripheral insulin-stimulated glucose uptake appears to be preserved.
Authors: G Johannsson; P Mårin; L Lönn; M Ottosson; K Stenlöf; P Björntorp; L Sjöström; B A Bengtsson Journal: J Clin Endocrinol Metab Date: 1997-03 Impact factor: 5.958
Authors: J Vittone; M R Blackman; J Busby-Whitehead; C Tsiao; K J Stewart; J Tobin; T Stevens; M F Bellantoni; M A Rogers; G Baumann; J Roth; S M Harman; R G Spencer Journal: Metabolism Date: 1997-01 Impact factor: 8.694
Authors: Julian Falutz; Soraya Allas; Koenraad Blot; Diane Potvin; Donald Kotler; Michael Somero; Daniel Berger; Stephen Brown; Gary Richmond; Jeffrey Fessel; Ralph Turner; Steven Grinspoon Journal: N Engl J Med Date: 2007-12-06 Impact factor: 91.245
Authors: Hideo Makimura; Meghan N Feldpausch; Alison M Rope; Linda C Hemphill; Martin Torriani; Hang Lee; Steven K Grinspoon Journal: J Clin Endocrinol Metab Date: 2012-09-26 Impact factor: 5.958
Authors: Takara L Stanley; Lindsay T Fourman; Meghan N Feldpausch; Julia Purdy; Isabel Zheng; Chelsea S Pan; Julia Aepfelbacher; Colleen Buckless; Andrew Tsao; Anela Kellogg; Karen Branch; Hang Lee; Chia-Ying Liu; Kathleen E Corey; Raymond T Chung; Martin Torriani; David E Kleiner; Colleen M Hadigan; Steven K Grinspoon Journal: Lancet HIV Date: 2019-10-11 Impact factor: 12.767
Authors: Takara L Stanley; Meghan N Feldpausch; Caitlin A Murphy; Steven K Grinspoon; Hideo Makimura Journal: Growth Horm IGF Res Date: 2013-11-15 Impact factor: 2.372
Authors: Seth D Friedman; Laura D Baker; Soo Borson; J Eric Jensen; Suzanne M Barsness; Suzanne Craft; George R Merriam; Randolph K Otto; Edward J Novotny; Michael V Vitiello Journal: JAMA Neurol Date: 2013-07 Impact factor: 18.302